Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Am Acad Dermatol. 2011 Jul;65(1):195-7. doi: 10.1016/j.jaad.2009.12.025. Epub 2011 Apr 19.

Is tuberculin skin testing reliable during anti-tumor necrosis factor-alfa therapy? A case report and review of the literature.

Author information

  • 1New York Medical College, Valhalla, New York, USA. madelaine_haddican@nymc.edu

Abstract

The increased risk to patients on anti-tumor necrosis factor-alfa therapy of developing active tuberculosis supports screening of these patients for latent tuberculosis infection. The current practice of determining the presence of latent tuberculosis infection primarily, and often entirely, depends on the use of tuberculin skin testing (TST). We report a patient with psoriasis on long-term etanercept therapy who had a negative TST result and a positive interferon-gamma release assay result. Similar cases have also been found through a review of the literature. These findings suggest that TST might be unreliable during long-term anti-tumor necrosis factor-alfa therapy. QuantiFeron-TB Gold testing may be a more appropriate primary test in patients with risk factors for false-negative TST results.

Copyright © 2010 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.

PMID:
21507516
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk